Clover Biopharmaceuticals, Ltd. (HKG:2197)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
2.970
+0.110 (3.85%)
Apr 29, 2026, 4:08 PM HKT
1,370%
Market Cap 3.86B
Revenue (ttm) 3.90M
Net Income (ttm) -228.23M
Shares Out 1.30B
EPS (ttm) -0.18
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,711,000
Average Volume 5,550,636
Open 2.860
Previous Close 2.860
Day's Range 2.780 - 3.030
52-Week Range 0.193 - 3.200
Beta 2.67
RSI 57.14
Earnings Date Mar 25, 2026

About Clover Biopharmaceuticals

Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research and development, manufacture, and commercialization of vaccines in Mainland China and internationally. The company’s product candidates include SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine; AdimFlu-S (QIS), a quadrivalent split inactivated vaccine for the treatment of influenza A and B; and SCB-219M, a thrombopoietin receptor agonist mimetic bispecific Fc-fusion protein to treat cancer patients with chemotherapy-induced thrombocytopenia. It is also developing SCB-... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2007
Employees 243
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2197
Full Company Profile

Financial Performance

In 2025, Clover Biopharmaceuticals's revenue was 3.51 million, a decrease of -90.88% compared to the previous year's 38.42 million. Losses were -205.09 million, -77.30% less than in 2024.

Financial numbers in CNY Financial Statements

News

Clover Biopharmaceuticals Reports Positive U.S. Phase I Data On RSV Re-Vaccination In Older Adults

(RTTNews) - Clover Biopharmaceuticals, Ltd. (2197.HK) announced new Phase I clinical trial results from the U.S. evaluating re-vaccination with its RSV PreF vaccine candidate (SCB-1019) compared head-...

5 weeks ago - Nasdaq